

**Fund Overview**

|                        |                             |
|------------------------|-----------------------------|
| Base Currency for Fund | USD                         |
| Total Net Assets (USD) | 1.79 billion                |
| Fund Inception Date    | 03.04.2000                  |
| Number of Issuers      | 74                          |
| Benchmark              | NASDAQ Biotechnology Index  |
| Morningstar Category™  | Sector Equity Biotechnology |

**Summary of Investment Objective**

The Fund aims to achieve capital appreciation by investing principally in equity securities of biotechnology companies and discovery research firms mainly located in the US.

**Fund Management**


Evan McCulloch, CFA: United States  
Wendy Lam, PhD: United States  
Steve Kornfeld, CFA: United States

**Ratings - Z (acc) GBP**

Overall Morningstar Rating™: ★ ★ ★

**Asset Allocation**

|                         |       |
|-------------------------|-------|
|                         | %     |
| Equity                  | 99.42 |
| Cash & Cash Equivalents | 0.58  |

**Performance**
**Performance over 5 Years in Share Class Currency (%)**

**Discrete Annual Performance in Share Class Currency (%)**

|                  | 10/18 | 10/17 | 10/16 | 10/15 | 10/14 |
|------------------|-------|-------|-------|-------|-------|
|                  | 10/19 | 10/18 | 10/17 | 10/16 | 10/15 |
| Z (acc) GBP      | 5.63  | -2.04 | 11.21 | 2.43  | 8.79  |
| Benchmark in GBP | 1.42  | 3.55  | 13.02 | -0.97 | 14.09 |

**Performance in Share Class Currency (%)**

|                  | Cumulative |        |        |      |       |       |              | Annualised |       |              |
|------------------|------------|--------|--------|------|-------|-------|--------------|------------|-------|--------------|
|                  | 1 Mth      | 3 Mths | 6 Mths | 1 Yr | 3 Yrs | 5 Yrs | Since Incept | 3 Yrs      | 5 Yrs | Since Incept |
| Z (acc) GBP      | 5.28       | -6.75  | 4.54   | 5.63 | 15.07 | 28.23 | 215.20       | 4.79       | 5.10  | 16.56        |
| Benchmark in GBP | 2.24       | -4.89  | 1.47   | 1.42 | 18.70 | 34.12 | 234.10       | 5.88       | 6.05  | 17.47        |

**Past performance is not an indicator or a guarantee of future performance.** The value of shares in the Fund and income received from it can go down as well as up, and investors may not get back the full amount invested. Performance details provided are in share class currency, include the reinvested dividends gross of basic rate UK tax and are net of management fees. Sales charges and other commissions, other taxes and relevant costs to be paid by an investor are not included in the calculations. Performance may also be affected by currency fluctuations. Up to date performance figures can be found on our local website.

When performance for either the portfolio or its benchmark has been converted, different foreign exchange closing rates may be used between the portfolio and its benchmark.

**Top Ten Holdings (% of Total)**

| Issuer Name                   |      |
|-------------------------------|------|
| AMGEN INC                     | 8.34 |
| VERTEX PHARMACEUTICALS INC    | 7.02 |
| GILEAD SCIENCES INC           | 6.26 |
| ILLUMINA INC                  | 4.91 |
| BIOGEN INC                    | 4.79 |
| REATA PHARMACEUTICALS INC     | 4.72 |
| GW PHARMACEUTICALS PLC        | 4.37 |
| ALEXION PHARMACEUTICALS INC   | 4.22 |
| REGENERON PHARMACEUTICALS INC | 4.17 |
| IOVANCE BIOTHERAPEUTICS INC   | 3.57 |

**Fund Measures**

|                                   |        |
|-----------------------------------|--------|
| P/E to Growth                     | 1.41x  |
| Historical 3 Yr Sales Growth      | 55.10% |
| Estimated 3-5 Yr EPS Growth       | 24.15% |
| Price to Earnings (12-mo Forward) | 15.72x |
| Standard Deviation (5 Yrs)        | 22.27% |

**Share Class Information** (For a full list of available share classes, please visit your local website)

| Share Class | Incept Date | NAV       | Ongoing Charges (%) | Fees                  |                        | Dividends |                | Fund Identifiers |              |
|-------------|-------------|-----------|---------------------|-----------------------|------------------------|-----------|----------------|------------------|--------------|
|             |             |           |                     | Max. Sales Charge (%) | Max. Annual Charge (%) | Frequency | Last Paid Date | SEDOL            | ISIN         |
| Z (acc) GBP | 04.05.2012  | GBP 31.52 | 1.32                | N/A                   | 1.00                   | N/A       | N/A            | B76CRG3          | LU0774687577 |

## Composition of Fund

| Market Capitalisation Breakdown in USD | % of Equity |
|--|-------------|
| <2.0 Billion                           | 18.32       |
| 2.0-5.0 Billion                        | 22.95       |
| 5.0-10.0 Billion                       | 15.47       |
| 10.0-25.0 Billion                      | 7.22        |
| 25.0-50.0 Billion                      | 9.13        |
| >50.0 Billion                          | 26.57       |
| N/A                                    | 0.33        |

## What are the Key Risks?

The value of shares in the Fund and income received from it can go down as well as up and investors may not get back the full amount invested.

Performance may also be affected by currency fluctuations. Currency fluctuations may affect the value of overseas investments.

The Fund invests mainly in equity securities of biotechnology companies. Such securities have historically been subject to significant price movements that may occur suddenly due to market, sector or company-specific factors. As a result, the performance of the Fund can fluctuate significantly over relatively short time periods.

The Fund may distribute income gross of expenses. Whilst this might allow more income to be distributed, it may also have the effect of reducing capital.

Other significant risks include: liquidity risk.

For full details of all of the risks applicable to this Fund, please refer to the "Risk Considerations" section of the Fund in the current prospectus of Franklin Templeton Investment Funds.

## Glossary

**Estimated 3-5 Yr EPS Growth:** An estimated measure of the growth of earnings per share over a forward-looking period. For a portfolio, the value represents a weighted average of the stocks it holds.

**Historical 3 Yr Sales Growth:** The rate at which sales have increased for the fund's underlying holdings over the last three years.

**P/E to Growth:** A ratio used to determine a stock's value while taking into account earnings growth. For a portfolio, the value represents a weighted average of the stocks it holds.

**Price to Earnings (12-mo Forward):** A measure of the price to earnings ratio for a stock using the forecasted earnings for the next 12 months. For a portfolio, the value represents a weighted average of the stocks it holds.

**Standard Deviation:** A measure of the degree to which a fund's return varies from the average of its previous returns. The larger the standard deviation, the greater the likelihood (and risk) that a fund's performance will fluctuate from the average return.

## Important Information

Given the variety of investment options available today, we suggest investors seek guidance from a Financial Adviser.

This document is intended to be of general interest only and does not constitute legal or tax advice nor is it an offer for shares or invitation to apply for shares of the Franklin Templeton Investment Funds SICAV (the Fund). Nothing in this document should be construed as investment advice. Subscriptions to shares of the Fund can only be made on the basis of the current prospectus and where available, the relevant Key Investor Information Document, accompanied by the latest available audited annual report and the latest semi-annual report if published thereafter. No shares of the Fund may be directly or indirectly offered or sold to residents of the United States of America. Shares of the Fund are not available for distribution in all jurisdictions and prospective investors should confirm availability with their local Franklin Templeton Investments representative before making any plans to invest. References to particular industries, sectors or companies are for general information and are not necessarily indicative of a Fund's holding at any one time. The value of shares in the Fund and income received from it can go down as well as up, and investors may not get back the full amount invested. All or most of the protections provided by the UK Regulatory System will not apply to Franklin Templeton Investment Funds (SICAV) Investors. An investment in the Fund entails risks which are described in the Fund's prospectus and where available, the relevant Key Investor Information Document.

Source for data and information provided by Franklin Templeton Investments, as of the date of this document, unless otherwise noted. Benchmark related data provided by FactSet, as of the date of this document, unless otherwise noted. References to indices are made for comparative purposes only and are provided to represent the investment environment existing during the time periods shown. An index is unmanaged and one cannot invest directly in an index. The performance of the index does not include the deduction of expenses and does not represent the performance of any Franklin Templeton fund.

The Fund invests in a specific sector or geographical area and the returns may be more volatile than a more diversified fund.

**Fund Management:** CFA® and Chartered Financial Analyst® are trademarks owned by CFA Institute.

**Ratings:** © Morningstar, Inc. All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.

**Top Ten Holdings:** These securities do not represent all of the securities purchased, sold or recommended for clients, and the reader should not assume that investment in the securities listed was or will be profitable. The portfolio manager for the Fund reserves the right to withhold release of information with respect to holdings that would otherwise be included in the top holdings list.

**Ongoing Charges:** The Ongoing Charges Figure (OCF) is an amount representing all operating charges and expenses of the Fund in the prior 12 months as a percentage of the Fund's average net assets for the period. Where that figure would not be a fair representation of future costs or if 12 months data is not available, an estimated figure will be shown.

Performance attribution is calculated in the base currency of the fund.

For a free copy of the latest prospectus, the relevant Key Investor Information Document, the annual report and semi-annual report, if published thereafter or for more information about any Franklin Templeton Investments' fund, UK investors should contact: Franklin Templeton Investments, Telephone: 0800 305 306, Email: [enquiries@franklintempleton.co.uk](mailto:enquiries@franklintempleton.co.uk) or write to us at the address below. Issued by Franklin Templeton Investment Management Limited (FTIML) Registered office: Cannon Place, 78 Cannon Street, London, EC4N 6HL. FTIML is authorised and regulated by the Financial Conduct Authority.